Custom Protein Expression, From Construct to Purified Protein
Recombinant protein expression services across E. coli, mammalian, insect, and yeast platforms — here's how the systems differ, what they're good for, and how to evaluate a provider before you commit a program to one.
Search volume and CPC via DataForSEO, US database.
What Is Custom Protein Expression?
Custom protein expression is the production of a specific protein of interest by introducing its gene sequence into a host cell — bacterial, mammalian, insect, or yeast — and inducing that cell to manufacture the protein at usable scale. The resulting material is then purified, characterized, and delivered for downstream use.
Labs and companies outsource this work rather than building expression capability in-house when a project needs a platform they don't maintain, a faster timeline than internal capacity allows, or scale-up beyond what a bench lab can support.
Four Expression Systems, Four Different Trade-Offs
There is no single best host organism — the right platform depends on the protein's complexity, what modifications it needs, and how the material will ultimately be used.
Bacterial (E. coli)
The fastest and lowest-cost platform, with a well-characterized genome and strong track record for simple, non-glycosylated proteins. Constructs can move from cloning to expressed protein in as little as 2-3 weeks. Limitations: no complex post-translational modifications, and some targets form insoluble inclusion bodies that require a refolding step. Endotoxin removal is required before any in vivo use.
Mammalian (CHO, HEK293)
The industry standard for proteins that need human-like folding, glycosylation, and disulfide bond formation. CHO cell lines are used across most approved biologics manufacturing, including GMP production; HEK293 is often used for faster transient expression during early-stage screening. Timelines run longer (4-10+ weeks) and cost more than microbial systems.
Insect / Baculovirus (BEVS)
The baculovirus expression vector system (BEVS) uses insect cell lines — commonly Sf9, Sf21, or Hi5 (Trichoplusia ni) — to produce large, multi-domain eukaryotic proteins that E. coli can't fold correctly. Glycosylation occurs but follows an insect (high-mannose) pattern rather than the human pattern, which matters for anything destined for clinical use. Also the standard route for virus-like particle (VLP) production.
Yeast (Pichia pastoris, S. cerevisiae)
A eukaryotic host capable of secretion, which simplifies downstream purification, and some post-translational processing. Pichia pastoris (now often classified as Komagataella phaffii) is favored for its methanol-inducible AOX1 promoter and ability to reach very high cell densities in fermentation, making it cost-effective to scale. Its glycosylation pattern is hypermannosylated relative to mammalian cells, a consideration for therapeutic targets.
Where Custom Protein Expression Gets Used
The same underlying technique supports very different downstream goals — from a single crystallography-grade sample to a manufacturing process headed toward the clinic.
Structural Biology
X-ray crystallography and cryo-EM both require highly pure, homogeneous protein, typically in milligram quantities. Expression system choice and purification tag design (His-tag, cleavable fusion partners) directly affect crystallization success.
Antibody Production
Recombinant monoclonal antibody expression is almost always run in mammalian systems (CHO or HEK293) to get correct glycosylation and Fc effector function — critical for both research-grade and therapeutic antibodies.
Therapeutic Development
Early discovery work can start in a fast, cheap system, but candidates advancing toward the clinic need a defined path to GMP-grade material, with full characterization and documentation to support IND-enabling studies.
Diagnostics & Assay Development
Recombinant antigens produced at consistent purity and lot-to-lot reproducibility are the backbone of ELISA kits, lateral flow assays, and other immunoassay formats.
Industrial & Research Enzymes
Bulk enzyme production for research reagents or industrial processes typically favors microbial or yeast fermentation for cost efficiency at scale.
Vaccine Antigen Production
Recombinant antigens and virus-like particles (VLPs), often produced via insect/baculovirus or yeast platforms, are used in both research and licensed vaccine manufacturing.
How to Evaluate a Protein Expression Provider
Providers vary widely in platform breadth, QC rigor, and scale-up capacity. Confirm the following before committing a program to one.
Expression System Flexibility
A provider with multiple platforms in-house (bacterial, mammalian, insect, yeast) can match the system to the protein instead of forcing every target through the same host.
Post-Translational Modification Requirements
Confirm whether your target needs glycosylation, disulfide bond formation, or other PTMs — this alone usually rules out or requires specific expression systems.
Purification & QC Standards
Ask what's included: SDS-PAGE, Western blot, mass spec identity confirmation, endotoxin testing, and aggregation/purity analysis (e.g., SEC-MALS) for anything downstream-sensitive.
Scale-Up Path
Milligram-scale for early research is very different from gram-scale preclinical material or GMP-grade clinical supply. Confirm the provider can carry a program through the stages it will actually need.
IP Protection & Confidentiality
A signed MTA and CDA/NDA should be standard before any construct or sequence information changes hands.
Turnaround Time & Communication
Typical custom expression timelines run 2-4 weeks for straightforward E. coli constructs and 4-10+ weeks for mammalian or insect systems — ask for a defined timeline with progress checkpoints, not just a final delivery date.
Regulatory Documentation
For anything moving toward IND-enabling or clinical use, confirm the provider can supply a Certificate of Analysis and, if needed, a defined path to GMP-compliant manufacturing.
Typical Project Timeline
Timelines vary by expression system, construct complexity, and scale — these ranges reflect what most custom expression projects fall into.
E. coli / bacterial constructs, research-scale
Mammalian or insect systems, complex proteins
GMP-grade scale-up for clinical programs
Frequently Asked Questions
Common questions researchers and procurement teams ask before starting a custom expression project.
What is custom protein expression?
Custom protein expression is the process of producing a specific protein of interest by inserting its gene sequence into a host organism — bacterial, mammalian, insect, or yeast cells — that is then grown and induced to manufacture that protein, which is subsequently purified for research or therapeutic use.
What's the difference between recombinant protein expression and protein expression services?
Recombinant protein expression describes the underlying technique — using recombinant DNA to direct a host cell to produce a target protein. Protein expression services is the commercial term for outsourcing that work to a contract lab or CRO rather than running it in-house.
Which expression system is right for my protein?
It depends on the protein's complexity and downstream use. Simple, non-glycosylated proteins are often fastest and cheapest in E. coli. Proteins requiring human-like folding and glycosylation — most antibodies and therapeutic candidates — typically need a mammalian system like CHO or HEK293. Large, complex, or membrane-associated proteins often go to an insect/baculovirus system. Yeast is a common middle ground for secreted proteins and industrial enzymes at scale.
How long does custom protein expression take?
Bacterial (E. coli) expression can move from construct to purified protein in roughly 2-4 weeks. Mammalian and insect cell systems generally take 4-10+ weeks depending on construct optimization, cell line development, and the scale and purity required.
Can custom expression services produce GMP-grade protein?
Some providers offer a defined path from research-grade to GMP-compliant manufacturing for programs advancing toward the clinic; others focus solely on research-grade material. Confirm this capability, and the documentation that comes with it, before committing to a provider for a therapeutic program.
What purity and yield can I expect?
This varies by protein and expression system, and should be specified in the project scope up front. Ask what analytical methods (SDS-PAGE, mass spec, SEC-MALS, endotoxin testing) are used to confirm purity and identity, and whether yield guarantees or re-runs are part of the agreement.
Do I retain ownership of my protein construct and sequence data?
Reputable providers work under a signed material transfer agreement (MTA) and confidentiality agreement (CDA/NDA) that protects the client's IP in the construct, sequence, and resulting protein. Confirm this in writing before sharing any proprietary sequence.
Request a Custom Protein Expression Quote
Tell us about your target protein and project goals, and we'll help you figure out which expression system and provider profile fits.